DUBLIN–(BUSINESS WIRE)–Feb 9, 2021– The "US Lung Cancer Market and Competitive Landscape – 2021" report has been added to ResearchAndMarkets.com’s offering. This latest research report provides comprehensive insights into Lung Cancer pipeline products, Lung Cancer epidemiology, Lung Cancer market valuations and forecast, Lung Cancer drug sales and a competitive landscape in the US. The research is classified into seven sections – Lung Cancer treatment options, pipeline products, market analysis comprising of epidemiology, key products marketed, market valuations and forecast, drugs sales and market shares. Research Scope:
- Lung Cancer pipeline: Find out the products in clinical trials for the treatment of Lung Cancer by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
- Lung Cancer epidemiology: Find out the number of patients diagnosed (prevalence) with Lung Cancer in the US
- Lung Cancer drugs: Identify key products marketed and prescribed for Lung Cancer in the US, including trade name, molecule name, and company
- Lung Cancer drugs sales: Find out the sales revenues of Lung Cancer drugs in the US
- Lung Cancer market valuations: Find out the market size for Lung Cancer drugs in 2019 in the US. Find out how the market advanced from 2017 and forecast to 2026
- Lung Cancer drugs market share: Find out the market shares for key Lung Cancer drugs in the US
Benefits of this Research: The research helps executives to
- Support monitoring and reporting national Lung Cancer market analysis and sales trends
- Track competitor drugs sales and market share in the US Lung Cancer market
- Track competitive developments in the Lung Cancer market and present key issues and learnings
- Synthesize insights for the Lung Cancer market and products to drive business performance
- Answer key business questions about the Lung Cancer market
- Evaluate commercial market opportunity assessment, positioning, and segmentation for Lung Cancer products
- Supports decision making in R&D to long term marketing strategies
Key Topics Covered: 1) Lung Cancer Treatments 2) Lung Cancer Pipeline 3) US Lung Cancer Epidemiology 4) Marketed Drugs for Lung Cancer in the US 5) US Lung Cancer Market Size and Forecast 6) US Lung Cancer Products Sales and Forecast 7) US Lung Cancer Market Competitive Landscape 8) Methodology 9) Contact us List of Tables 1. Lung Cancer Phase 3 Clinical Trials, 2021 2. Lung Cancer Phase 2 Clinical Trials, 2021 3. Lung Cancer Phase 1 Clinical Trials, 2021 4. Lung Cancer Epidemiology, US, 2017 – 2026 5. Marketed Drugs for Lung Cancer, US, 2020 6. Lung Cancer Market Size and Forecast ($), US, 2017 – 2026 7. Lung Cancer Product Sales ($), US, 2017 – 2026 List of Figures 1. Lung Cancer Epidemiology, US, 2017 – 2026 2. Lung Cancer Market Size and Forecast ($), US, 2017 – 2026 3. Lung Cancer Products Market Share (%), US, 2019 For more information about this report visit https://www.researchandmarkets.com/r/so2llh View source version on businesswire.com:https://www.businesswire.com/news/home/20210209005528/en/ CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: PHARMACEUTICAL HEALTH ONCOLOGY SOURCE: Research and Markets Copyright Business Wire 2021. PUB: 02/09/2021 04:24 AM/DISC: 02/09/2021 04:24 AM http://www.businesswire.com/news/home/20210209005528/en
